Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Executive Summary

Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program
Advertisement

Related Content

Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
American Heart Association Scientific Sessions, In Brief
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
CETP Trials Still Inhibited As Torcetrapib Results Fail To Illuminate Outcomes
Roche Puts “Mind Towards” Phase III For CETP Inhibitor
Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center
Roche Diagnostics CEO Is No Ugly Duckling: Schwan Picked To Head Parent Corp.
Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest
Kindler appointed Pfizer chairman
Advertisement
UsernamePublicRestriction

Register

PS047833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel